Outlook Therapeutics (NASDAQ: OTLK) saw its shares climb approximately 26% on Wednesday, trading near $0.89, as investors reacted positively to the company's announcement that the U.S. Food and Drug Administration (FDA) had accepted its Biologics License Application (BLA) resubmission for Lytenava (ONS-5010) under a Class 1 review designation. The stock traded between $0.6853 and $0.8999 on heavy volume of roughly 21.9 million shares, reflecting heightened interest in the potential approval timeline for the wet age-related macular degeneration (AMD) treatment.
FDA Review and Timeline
On June 1, Outlook Therapeutics resubmitted its BLA for Lytenava, a bevacizumab-based ophthalmic formulation targeting neovascular (wet) AMD, a leading cause of central vision loss. The FDA's Office of New Drugs had previously granted the company's appeal through the Formal Dispute Resolution process, concluding that “substantial evidence of effectiveness has been established” for Lytenava. The Class 1 review designation means the FDA will issue a decision within 60 days of receiving the application, a significantly shorter timeline compared to the standard review process.
This marks a pivotal shift from late 2025, when Outlook faced a second Complete Response Letter (CRL) from the FDA, which had refused approval and requested additional confirmatory efficacy data. The new review is characterized as a labeling process rather than a demand for further clinical trials, with the FDA's Division of Ophthalmology and Office of Specialty Medicine involved in final product labeling discussions.
Market Position and Competitive Landscape
Lytenava, if approved, would become the first FDA-approved bevacizumab eye drug for retinal conditions in the U.S. It is designed to block vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel growth and leakage in the retina. The drug would compete with established anti-VEGF therapies such as Roche's Lucentis and Vabysmo, as well as Regeneron's Eylea. Outlook has already secured marketing authorization in the European Union and the United Kingdom, with commercial rollout underway in Germany, Austria, and the U.K., though pricing and reimbursement negotiations in certain EU markets remain ongoing.
Nasdaq Compliance and Financial Risks
Despite the positive regulatory news, Outlook Therapeutics continues to face significant headwinds. The stock remains below the $1.00 minimum bid price required for continued listing on the Nasdaq, giving the company until August 17, 2026, to regain compliance by closing at $1.00 or above for ten consecutive trading days. To address this, Outlook has called a special shareholder meeting on July 16, 2026, to vote on a reverse stock split proposal ranging from 1-for-10 to 1-for-50. Shareholders will also consider increasing authorized common shares from 260 million to 600 million, along with additional shares tied to warrant exercises.
Financial sustainability remains a pressing concern. In its March-quarter filing, Outlook reported only $7.7 million in cash and cash equivalents as of March 31, 2026, and acknowledged that this amount, combined with proceeds from an April offering, would not cover 12 months of operations. The company has raised substantial doubt about its ability to continue as a going concern, underscoring the need for additional financing, which could lead to further shareholder dilution.
Outlook and Key Catalysts
Investors are closely watching whether the FDA's positive review trajectory can translate into U.S. approval before the Nasdaq compliance deadline or a potential reverse split. A favorable FDA decision would not only validate Lytenava's efficacy but also provide a critical catalyst for the stock. Conversely, any negative labeling, delays, or outright rejection could exacerbate the company's financial strain and erode investor confidence. The next few weeks will be decisive as the market awaits the FDA's PDUFA decision within the 60-day window.